Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML. [PDF]
Short NJ +21 more
europepmc +1 more source
Fatal Bone marrow necrosis following azacitidine and granulocyte colony-stimulating factor administration in a patient with high-risk myelodysplastic syndrome [PDF]
論文(Article)Azacitidine, which has the capacity to induce DNA hypomethylation in vitro, is currently available for treatment of myelodysplastic syndrome (MDS).
加藤, 丈夫 +4 more
core
Timdarpacept (IMM01) combined with azacitidine (AZA) as first-line therapy in adults with higher risk chronic myelomonocytic leukemia (CMML): results from a prospective, multicenter, phase II study. [PDF]
Ma L +18 more
europepmc +1 more source
Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis. [PDF]
Williamson J +5 more
europepmc +1 more source
The Impact of Induction With Azacitidine and Venetoclax Versus Intensive Chemotherapy on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia. [PDF]
Wirk B, Hawila R.
europepmc +1 more source
Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth. [PDF]
Zou X +6 more
europepmc +1 more source
Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy. [PDF]
Thammagul K +5 more
europepmc +1 more source
DNA Hypomethylation Is Not Cell Intrinsically Toxic to Polycomb Repressive Complex 2 Deficient Malignant Peripheral Nerve Sheath Tumors. [PDF]
Stahl MR +4 more
europepmc +1 more source
A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T-Cell Lymphoma. [PDF]
Saeed H +15 more
europepmc +1 more source
Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus. [PDF]
Schuh AC +10 more
europepmc +1 more source

